---
document_datetime: 2023-09-21 21:29:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/pyrukynd-epar-all-authorised-presentations_en.pdf
document_name: pyrukynd-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0192941
conversion_datetime: 2025-12-19 22:35:49.18433
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size

| EU/1/22/1662/001   | Pyrukynd   | 5 mg          | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/alu)   | Taper pack: 7 tablets                          |
|--------------------|------------|---------------|----------------------|------------|---------------------------|------------------------------------------------|
| EU/1/22/1662/002   | Pyrukynd   | 5 mg          | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/alu)   | 56 tablets                                     |
| EU/1/22/1662/003   | Pyrukynd   | 5 mg + 20 mg  | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/alu)   | Taper pack: 14 tablets (7 x 5 mg + 7 x 20 mg)  |
| EU/1/22/1662/004   | Pyrukynd   | 20 mg         | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/alu)   | 56 tablets                                     |
| EU/1/22/1662/005   | Pyrukynd   | 20 mg + 50 mg | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/alu)   | Taper pack: 14 tablets (7 x 20 mg + 7 x 50 mg) |
| EU/1/22/1662/006   | Pyrukynd   | 50 mg         | Film-coated tablet   | Oral use   | blister (PVC/PCTFE/alu)   | 56 tablets                                     |